Novo Nordisk CEO to testify in US Senate hearing on high cost of Ozempic, Wegovy
By Thomson ReutersJun 14, 2024 | 4:42 PM
(Reuters) – The U.S Senate Committee on Health, Education, Labor, and Pensions said on Friday that Novo Nordisk CEO Lars Jorgensen has agreed to testify voluntarily in a September hearing focusing on U.S. prices for weight loss drugs Ozempic and Wegovy.
(Reporting by Puyaan Singh in Bengaluru)
For the health and safety of everyone, our offices are temporarily closed to the public. If you have won a prize from us we will be mailing it to you or will contact you with specific information needed to redeem your prize. Feel free to call us with questions during weekday business hours at 715-842-1672.
